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ABSTRACT
Owing to a striking, and most likely fortuitous,
structural and sequence similarity with the bacterial
16S ribosomal A site, the RNA kissing-loop complex
formed by the HIV-1 genomic RNA dimerization ini-
tiation site (DIS) specifically binds 4,5-disubstituted
2-deoxystreptamine (2-DOS) aminoglycoside anti-
biotics. We used chemical probing, molecular
modeling, isothermal titration calorimetry (ITC) and
UV melting to investigate aminoglycoside binding to
the DIS loop–loop complex. We showed that apra-
mycin, an aminoglycoside containing a bicyclic
moiety, also binds the DIS, but in a different way
than 4,5-disubstituted 2-DOS aminoglycosides.
The determination of thermodynamic parameters
for various aminoglycosides revealed the role of the
different rings in the drug–RNA interaction.
Surprisingly, we found that the affinity of lividomycin
and neomycin for the DIS (Kd 30nM) is significantly
higher than that obtained in the same experimental
conditions for their natural target, the bacterial A
site (Kd 1.6mM). In good agreement with their
respective affinity, aminoglycoside increase the
melting temperature of the loop–loop interaction
and also block the conversion from kissing-loop
complex to extended duplex. Taken together, our
data might be useful for selecting new molecules
with improved specificity and affinity toward the
HIV-1 DIS RNA.
INTRODUCTION
Up to now, the ﬁght against HIV essentially relied on
multitherapies targeting two out of the three viral
enzymes: reverse transcriptase (16 inhibitors approved
by the US Food and Drug Administration, FDA) and
protease (11 inhibitors approved by the FDA). However,
the high mutation and recombination rates of HIV,
together with its high replication level, easily allows
selection of drug-resistant viruses, thus reinforcing the
urgent need for targeting new viral molecules, such as
the viral integrase or cellular factors required for HIV-1
replication. Because of the increased interest for RNA in
the last few years, several studies pointed out that it could
also be an interesting target for small drugs (1–3).
Some functional sites within HIV-1 genomic RNA have
already been proposed as potential candidates, as the
Tat-responsive element TAR (4) or the Rev-responsive
element RRE (5), both interacting with the aminoglyco-
side antibiotic neomycin.
The dimerization initiation site (DIS) of the HIV-1
genomic RNA also constitutes a potentially interesting
target since this conserved stem–loop located in the
50-untranslated region is essential for genome dimerization
(6,7), facilitates recombination (8,9) and is required for
eﬃcient RNA packaging (7,10) and reverse transcription
(7,11). The DIS loop is made of nine nucleotides, six of
them forming a self-complementary sequence that pro-
motes genome dimerization by forming a loop–loop
complex (also called kissing-loop complex) (12–15),
stabilized by ﬂanking unpaired purines (16,17)
(Figure 1a). It was shown on short RNA fragments that
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Figure 1. HIV-1 DIS and aminoglycosides. (a) Localization of the DIS in the 50-untranslated region of the HIV-1 genomic RNA, sequence and
secondary structure of DIS stem-loops used in this study. The sequence represented here corresponds to HIV-1 subtype A. Sequence variations
observed for HIV-1 subtypes B and F are indicated in black and white boxes, respectively. (b) Chemical structure of apramycin, hygromycin and of
4,5-disubstituted DOS derivatives used in this study.
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in vitro into an extended duplex form by extension
of inter-strand Watson–Crick base pairs (18–20). This
conversion is facilitated either by an incubation of the DIS
dimer at 558C, or by the viral nucleocapsid protein
NCp7at 378C, and might take place during maturation of
the viral particle. We have previously solved the crystal
structure of the DIS duplex (21) and DIS loop–loop
complex (22,23) forms. The kissing-loop complex revealed
an unexpected resemblance with the bacterial 16S ribo-
somal A site, which is the target of aminoglycoside anti-
biotics. We showed that, due to structural and sequence
similarities, 4,5-disubstituted 2-desoxystreptamine (2-DOS)
aminoglycosides, but not 4,6-disubstituted 2-DOS ones,
could also speciﬁcally bind the DIS kissing-loop with a
geometry similar to that observed in the A site (24). In
agreement with these early ﬁndings, we have recently
solved crystal structures of the DIS kissing-loop in
complex with several 4,5-disubstituted 2-DOS aminogly-
cosides and we have shown that the DIS remains
accessible to these small drugs within the frame of the
complete genome in HIV-1 infected human cells and in
viral particles (25,26).
Apramycin and hygromycin B diﬀer in structure from
other aminoglycosides (Figure 1b). Apramycin is made of
a 4-monosubstituted 2-DOS scaﬀold containing a bicyclic
ring and hygromycin B is made of a 5-monosubstituted
2-DOS with a two ester linkage between rings II and III.
Antibacterial activity of these two antibiotics mainly
results from blocking ribosome translocation and not
by inducing miscoding during translation as for 4,5- and
4,6-disubstituted 2-DOS aminoglycosides (27,28).
Here we showed that apramycin, but not hygromycin,
also recognizes the DIS kissing-loop complex; however, its
mode of interaction diﬀers from that of 4,5-disubstituted
2-DOS aminoglycosides. Binding free energies of various
aminoglycosides to the DIS kissing-loop were obtained by
ITC microcalorimetry, revealing a nanomolar aﬃnity for
lividomycin and neomycin. These data correlate well with
the stabilization of the loop–loop interaction induced by
these compounds, as monitored by UV-melting. This
stabilization blocks the heat-assisted DIS kissing-loop to
extended duplex conversion. These results are in agree-
ment with previous in vitro data on much larger viral
RNA fragments and ex vivo studies and should be
valuable for the development of modiﬁed aminoglycosides
with improved speciﬁcity and aﬃnity toward the viral
genome.
MATERIALS AND METHODS
Sample preparation
The wild-type 23-mer HIV-1 subtype A DIS RNA, the
23-mer DIS U275C mutant, the 27-mer DIS variant with
a stabilized intramolecular stem, and the A site construct,
were purchased from Dharmacon (Lafayette, CO, USA).
For puriﬁcation, RNAs were loaded on a Nucleopac
PA-100 column (Dionex, Sunnyvale, CA, USA) heated
at 708C and equilibrated in 4M urea, 20mM
Mes [2-N(-Morpholine) ethane sulfonic acid], pH 6.2,
and eluted using a NaClO4 gradient. All aminoglycosides
were purchased from Sigma-Aldrich and used without
further puriﬁcation, except neamine, which was obtained
from neomycin by acidic treatment as described (29).
Kissing-loop complexes were obtained as follows: RNA
was diluted to 2mM [maximum concentration to avoid
signiﬁcant amount of duplex species, see Ref. (30)] in
water, heat-denatured at 908C for 5min, and then cooled
on ice. The A site construct was taken from Ref. (31) and
prepared as follows: RNA was diluted to 100mM in water
(to facilitate intermolecular interactions), heated at 908C
for 5min and cooled to room temperature.
Lead-induced RNA cleavage
Lead(II)-induced cleavage was performed in a buﬀer
containing 2mM magnesium acetate, 20mM sodium
cacodylate pH 7.0, 25mM potassium acetate. The
23-mer DIS kissing-loop complex was incubated for
15min at 258C in the presence of 5mM lead(II) acetate.
The cleavage reaction was stopped by addition of 19mM
EDTA and by placing the sample in ethanol at  708Ci n
dry ice. The cleavage was revealed using 50[g
32P]ATP-
labeled RNA as a tracer. Products were analyzed by gel
electrophoresis on a denaturing 8M urea, 20% poly-
acrylamide gel.
Molecular modeling
The DIS–apramycin model was obtained by superimpos-
ing C1 atoms of residues 1405–1409, 1491, 1494 and 1495
in the crystal structure of the apramycin–A site complex
(PDB ID 1YRJ) to their DIS counterparts in the crystal
structure of the DIS–lividomycin complex (PDB ID
2FD0), resulting in an r.m.s.d. of 0.5A ˚ on these atoms.
Using program O (32), the position of the apramycin was
slightly modiﬁed (by translation and rotations) to max-
imize interactions with the DIS RNA. No structural
modiﬁcations of the RNA were required. Energy mini-
mization of the model was performed with CNS (33).
Isothermal titration calorimetry (ITC)
ITC measurements were performed at 258C on a MicroCal
VP-ITC (MicroCal, Northampton, MA, USA). The buﬀer
contained 25mM potassium acetate, 2mM magnesium
acetate, 20mM sodium cacodylate, pH 7.0. Low-salt
conditions were chosen at this temperature to avoid
conversion of the kissing-loop dimer into the extended
duplex form (30). In a typical experiment, 5ml aliquots of
aminoglycoside (100 or 200mM solution) were injected
into a 2mM DIS kissing-loop complex (1.42ml sample
cell). The duration of each injection was 10s and the delay
between injections was 120 or 240s. ITC titration curves
were analyzed using the software Origin (OriginLab,
Northampton, MA, USA). All data obtained with the
DIS RNA (excepted with lividomycin) were ﬁtted with a
three sequential binding site model (the two speciﬁc sites
observed in crystal structures, plus one ‘average site’
aimed at describing all unspeciﬁc binding resulting from
electrostatic interactions). Data obtained with the DIS
and lividomycin, as well as data with the bacterial A site
and any antibiotics, were ﬁtted with two independent
7130 Nucleic Acids Research, 2007, Vol. 35, No. 21binding sites, resulting in a signiﬁcant better ﬁt. Standard
free energies of binding and entropic contributions
were obtained, respectively, as  G= RT ln(Ka) and
T S= H  G, from the Ka and  H values derived
from ITC curve ﬁtting. In our experimental conditions,
the product Ka [RNA] N, where N is the number of
binding sites, lies in the 0.1–1000 range (0.4 for
ribostamycin to 125 for lividomycin), allowing an accurate
and simultaneous determination of binding parameters by
ITC (34). It has been shown by Pilch and coworkers (35)
that for aminoglycoside binding to the ribosomal A site,
the intrinsic binding enthalpy  Hint diﬀers from the
observed binding enthalpy  Hobs and can be obtained by
the following equation:
 Hobs ¼  Hint þ  Hion n
where  Hion represents the heat of ionization from the
considered buﬀer, and  n the number of protons linked to
binding at a speciﬁc pH. This correction (a minor one in
our case) was applied using the ionization heat ( Hion) for
cacodylate at 258C[  0.47kcal mol
 1 per proton accord-
ing to Ref. (36)] and the  n values determined in Ref. (37)
to derive the intrinsic binding enthalpies presented in
Table 1.
UV-melting studies
The 27-mer DIS variant sequence with a stabilized
intramolecular stem was diluted to 2.5mM in 500mlo f
water, heat-denatured at 908C for 5min and chilled at
08C. After 10min at this temperature, 55.5mlo fa1 0  
concentrated buﬀer (made with 250mM potassium
acetate, 500mM magnesium acetate and 200mM sodium
cacodylate, pH 7.0) was added. The sample was then
placed at 208C for 10min and 1ml of a 6mM aminoglyco-
side solution was added to the RNA sample (10.7mM ﬁnal
antibiotic concentrations). Absorbance versus tempera-
ture melting curves were measured at 260nm with a
heating rate of 0.58Cmin
 1 on a UVIKON-XL spectrom-
eter (SECOMAM, Domont, France) equipped with a
Peltier thermo-stated cell holder. Each melting experiment
in presence of aminoglycoside was performed six times for
better statistics. UV-melting curves and their derivatives
were smoothed with a Fourier-based ﬁltering procedure
programmed with Mathematica (Wolfram Res.,
Champaign, IL, USA).
DISkissing-loop to extended duplex conversion
DIS 23-mer containing a 5-bromouridine on U3 was
folded as a kissing-loop at a 12mM concentration (in
RNA stands) in a buﬀer containing 25mM potassium
acetate and 20mM sodium cacodylate pH 7.0. For each
experiment, 1.2ml of aminoglycoside at a 1mM concen-
tration was added to 11.1ml of RNA sample and
incubated 1h at 20 or 558C (in an incubator to avoid
condensation of water on the Eppendorf tube and sample
concentration). Each sample was then loaded in a 15%
polyacrylamide gel, either in semi-denaturing conditions
(TB 1 , migration at room temperature, 6W), or in a
native conditions (TB 1 , magnesium chloride 1mM,
migration at 48C, 6W). The gel was then stained in
ethidium bromide for analysis.
RESULTS AND DISCUSSION
Apramycin binding tothe DISkissing-loop complex
Chemical footprinting using lead(II) acetate was used to
investigate apramycin and hygromycin B binding to
the DIS kissing-loop complex. Using this method, it
was previously shown that neomycin, paromomycin and
lividomycin completely protect the DIS kissing-loop com-
plex from a speciﬁc lead(II)-induced cleavage (24,26).
An almost complete protection of the DIS RNA was also
observed upon addition of 25mM of apramycin. The
protection was slightly weaker than that observed at the
same concentration of paromomycin or neomycin, but
similar to the protection observed with lividomycin
(Figure 2). This result conﬁrms a recent report indicating
that apramycin binds the DIS kissing-loop (38). However,
no signiﬁcant protection was observed with hygromycin
(Figure 2), even when using millimolar concentrations of
drug (data not shown).
Structural insight into the apramycin/DIS complex
was obtained by 3D molecular modeling starting
from the X-ray structure of apramycin bound to the
Table 1. Binding parameters obtained by ITC measurements for aminoglycoside binding to the HIV-1 subtype A DIS kissing-loop complex and for
neomycin with the bacterial ribosomal A site
Kd (mM)  G (kcal mol
 1)  Hint (kcal mol
 1) T S (kcal mol
 1) Number of charges/
contact surface area
Neamine 8.7 ( 0.4)  6.9 ( 0.03)  40.5 ( 25)  33.6 ( 25) 4/538A ˚ 2
Ribostamycin 10.4 ( 1.4)  6.8 ( 0.08) ND ND 4/565A ˚ 2
Paromomycin 1.3 ( 0.2)  8.0 ( 0.09)  36.2 ( 7)  29.4 ( 7) 4/915A ˚ 2
Neomycin 0.034 ( 0.005)  10.2 ( 0.09)  9.4 ( 2) 0.8 ( 2) 6/915A ˚ 2
Lividomycin 0.032 ( 0.007)  10.2 ( 0.13)  17.5 ( 2)  7.3 ( 2) 5/1044A ˚ 2
Apramycin 5.8 ( 1.1)  7.1 ( 0.11)  51.7 ( 11)  44.6 ( 11) 5/–
Tobramycin 14.5 ( 0.1)  6.6 ( 0.01) ND ND 4/–
Neomycin (A site) 1.55 ( 0.07)  7.9 ( 0.03)  16.2 ( 1.0)  8.3 ( 1.0) 6/–
 Hint was calculated from  Hobs as described in the Methods section. ND stands for ‘not determined’, since accurate values of  H could not be
obtained. The  S value for neomycin is null within experimental errors. The number of expected positive charges as well as the drug/RNA contact
surface area for known structures are also indicated [taken from Ref. (25)], excepted for paromomycin where the contact surface area was
extrapolated for the neomycin/DIS structure.
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HIV-1 subtype F DIS kissing-loop complex as observed
in the crystal structures with aminoglycosides (26), since
docking to unliganded structures of the kissing-loop
complex led to a steric clash with the bicyclic moiety of
apramycin. The bound structures mainly diﬀer from the
unliganded kissing-loop by a shift from a C20-endo to a
C30-endo conformation of G271 upon drug binding. The
model revealed a diﬀerent binding pattern of apramycin as
compared to 4,5-disubstituted 2-DOS aminoglycosides
(Figure 3a). First, the latter interact with the loop–loop
helix and the major groove of both stems, whereas
apramycin interacts also with the loop–loop helix but
with the minor groove of both stems (Figure 3a). Second,
according to the model, apramycin probably enters the
kissing-loop through the minor groove of the RNA
whereas, according to the X-ray structures, 4,5-disubsti-
tuted 2-DOS aminoglycosides most likely enter through
the major groove (Figure 3a).
According to the model, the 2-DOS ring occupies the
same position in the apramycin/DIS and 4,5-disubstituted
2-DOS aminoglycosides/DIS complexes (Figure S1).
It interacts simultaneously with both RNA strands in
the loop–loop helix (Figure 3b and c) and achieves a
sequence-speciﬁc recognition of the RNA through inter-
actions with the bases of A278, C279, G2740, U2750 and
G2760 (the prime stands for the second RNA strand)
(Figure S2). Since U275 and A278 are involved into
apramycin recognition, we can anticipate that, as already
observed for other aminoglycosides (24,26), apramycin
binding to the DIS will be restricted to HIV-1 subtypes
with a 50GU275GCA278C30 DIS self-complementary
sequence in the loop, therefore excluding HIV-1 subtype
B DIS with a 50GC275GCG278C30 sequence. Similarly to
ring I of the neamine class aminoglycoside, the bicyclic
moiety of apramycin is involved in a pseudo Watson–
Crick base pair with the unpaired A280 (Figure 3b and c),
thus preventing any ﬂipped-in conformation of purines
272 and 273. Because of the protrusion of its ring III in the
minor groove close to bulged-out purines 272 and 273
(Figure 3a and b), apramycin might indirectly interact
with these bases through water molecules or ions and
inﬂuence their syn/anti conformation: such a conforma-
tional ﬂexibility was observed in crystal structures of
subtype A DIS kissing-loop complexes (22,23). Finally,
ring III of apramycin interacts with the sugar-phosphate
backbone of A282 and G271, as well as with the sugar
edge of G271 (Figure 3b and c). In addition to 12 possible
direct drug/RNA interactions suggested by the model,
several water- or ion-mediated interactions likely reinforce
the binding, as observed for neamine-class aminoglyco-
sides (26), but these cannot be reasonably predicted by a
model.
The crystal structure of a bacterial 30S ribosomal
subunit (containing the A site) bound to hygromycin (40)
was also used to build a DIS/hygromycin model (data not
shown) in order to understand the lack of binding.
It appears that, unlike apramycin and 4,5-disubstituted
2-DOS aminoglycosides, hygromycin would require an
inversion of the C269–G283 base pair into G269–C283, as
observed in the bacterial ribosomal A site. This diﬀerence
with the A-site precludes hygromycin binding to the DIS
dimer.
Determination ofthe thermodynamicparameters of
aminoglycoside/DIS binding and comparisonwith theA site
Isothermal titration calorimetry (ITC) was used to
characterize aminoglycoside binding to the DIS kissing-
loop complex. Unlike other techniques such as chemical
footprinting or ﬂuorescence spectroscopy that are indirect
methods, ITC directly provides a full thermodynamic
proﬁle of the drug/RNA interaction (34) and does not
require any modiﬁcation of the RNA for labeling. In
addition, this method was already successfully employed
to characterize aminoglycoside/A site interactions
(35,37,41–43). We investigated the binding to the HIV-1
subtype-A DIS of neamine, ribostamycin, paromomycin,
neomycin, lividomycin, apramycin and tobramycin.
Experimental conditions were chosen to be compatible
with the DIS kissing-loop complex and to avoid any
interference with the spontaneous conversion into the
extended duplex form of the DIS in the timescale of the
experiment (30): RNA concentration did not exceed 2mM
in a low-salt buﬀer, and the temperature was set to 258C.
Great care was taken to estimate the unspeciﬁc binding of
the positively charged aminoglycoside antibiotics on the
RNA. For that goal, we monitored their binding to a
standard A-form RNA helix of 22bp with a sequence very
similar to that of the DIS, but deprived of unpaired
residues and base-pair mismatches and thus of speciﬁc
binding sites (Figure S3). Unspeciﬁc interactions were
also investigated with a DIS hairpin monomer using
a DIS U275C mutant that cannot form a kissing-loop
Figure 2. Inhibition of the lead-induced cleavage by aminoglycosides
hygromycin, neomycin, paromomycin, apramycin and lividomycin.
Numbers correspond to mM concentration of the antibiotic. (-Pb) and
(0) correspond to control lanes without aminoglycoside, without and
with lead(II) acetate, respectively.
7132 Nucleic Acids Research, 2007, Vol. 35, No. 21dimer, as well as with a HIV-1 subtype-B DIS sequence
that is not recognized by aminoglycosides (24). The
4,6-disubstituted 2-DOS tobramycin that does not bind
the DIS kissing-loop (24) was also used to determine
aminoglycoside unspeciﬁc binding to the wild-type sub-
type A DIS kissing-loop complex. As expected, all these
situations were characterized by a weak exothermic signal
(Figure 4a) and led essentially to superimposable titration
curves (Figure S3). They can therefore be considered as
typical titration curves for unspeciﬁc aminoglycoside/
RNA interactions.
As observed for the A site, speciﬁc aminoglycoside
binding to the DIS is followed by exothermic heat
bursts due to protonation of several amino groups
(37). It has been shown that aminoglycoside binding
to the A site is strongly dependent on the pH and on
drug protonation: at low pH, already protonated amino-
glycosides bind with a higher aﬃnity to the A site than
at high pH, resulting in lower exothermic signal and a
reduced enthalpic contribution (35,37). We conducted our
ITC experiments at pH 7.0 to take beneﬁt of a rather large
calorimetric signal and to obtain binding parameters at
physiological pH. Figure 4 shows representative ITC
proﬁles for speciﬁc binding resulting from the injection of
neamine (b) and lividomycin (c) in a solution of subtype-A
DIS kissing-loop complex at pH 7.0. No assumption was
made about the cooperativity of the two binding sites
within a kissing-loop complex. Based on crystal structures,
some anti-cooperativity was possible because of the close
proximity of the two positively charged N1 positions of
the 2-DOS ring ( 4.4A ˚ ). Fitting of titration curves,
however, yielded almost identical equilibrium constants
(a)
(b)
(c)
Figure 3. (a) Representation of the solvent accessibility surface of aminoglycosides (probe radius 1.4A ˚ ) in the DIS/lividomycin crystal structure (left)
and the DIS/apramycin model (right) with the same orientation of the RNA kissing-loop complex. These views clearly depict the diﬀerent binding
geometry of these two aminoglycosides. (b) Two diﬀerent stereoviews of the apramycin–DIS complex showing direct RNA–drug interactions (black
lines). Dotted lines on the top view indicate probable water-mediated drug–RNA interaction. (c) Expected apramycin–RNA direct interactions
deduced from the model.
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fourth between two successive binding sites), leading to
the conclusion that they can be considered as independent
and equivalent.
In agreement with our previous chemical probing data
(26), lividomycin and neomycin were the strongest binders
with sub-micromolar aﬃnities (Table 1), followed by
paromomycin. It was shown that only these three drugs
are able to eﬃciently protect the DIS of large HIV-1 RNA
fragments toward chemical probes (26). The aﬃnity drops
to  10mM for neamine and ribostamycin, which were
ineﬃcient in footprinting experiments. This conﬁrms that,
as anticipated from our previous studies, rings IV and V
are extremely important for aminoglycoside aﬃnity,
although they interact only unspeciﬁcally with the RNA
sugar-phosphate backbone. By contrast, rings I, II and III
provide all structure- and sequence-speciﬁc contacts.
Interestingly, as already observed for the bacterial A site
(44), the aﬃnity of neamine is higher than that of
ribostamycin despite the larger number of drug–RNA
interactions in the DIS/ribostamycin complex. An inter-
mediate Kd value was obtained for apramycin (5.8mM),
which protects the 23-nt DIS signiﬁcantly better than
neamine against lead-induced cleavage. Finally, only
unspeciﬁc binding was observed with tobramycin
( 14mM), in agreement with the previous results (24).
It is nevertheless obvious that unspeciﬁc binding is variable
and depends on the number of positive charges of each
antibiotic molecule. Aﬃnities determined by ITC are
roughly consistent with values obtained by ﬂuorescence
techniques (38). Diﬀerences might be due to perturbations
of the conformation of purines 272 and 273 when they are
substituted by 2-aminopurines (2AP) for ﬂuorescence
labeling. Indeed, it has been shown for the A site that
substitution of unpaired adenines by 2-AP aﬀects the
bulged-in/-out equilibrium (45) and that A-2AP base pairs
are more stable than A–A interactions (Figure S4).
The observed standard free energies ( Gexp) were then
compared to drug/RNA interacting surface area deduced
from X-ray structures (25), and to the number of positive
charges. For that goal, calculated free energies ( Gcalc)
were estimated according to the simple linear model:
 Gcalc ¼  N þ  S
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Figure 4. ITC proﬁles for the titration of (a) lividomycin on the monomeric DIS U275C mutant, which is typical of unspeciﬁc binding, (b)o f
neamine and (c) of lividomycin on the subtype A DIS kissing-loop, which are typical of weak and strong speciﬁc binding, respectively. Each heat
burst curve is the result of a 5ml injection of 200mM drug in a 2mM RNA solution (1.42 sample cell). (d) Comparison of the measured free energy
(iGexp) and the calculated free energy (iGcalc) based on charge number and drug/RNA contact surface area observed in crystal structures. Since
no crystal structure of the paromomycin/DIS complex was obtained, surface area for paromomycin was considered to be identical to the neomycin
one (similar contacts are expected).
7134 Nucleic Acids Research, 2007, Vol. 35, No. 21where N is the number of positive charges of the drug, and
S is the drug/RNA contact surface area. Linear regression
yielded a= 1.1 ( 0.15) kcal mol
 1 per positive charge
and  = 1.0kcalmol
 1 for 240 ( 45) A ˚ 2. As simple as
it may be, this model yields a rather good correlation
between observed and calculated  G (Figure 4d).
However, such numerical values are DIS-speciﬁc, partic-
ularly for the term a, which should be strongly structure-
dependent. In the present situation, the fraction of free
energy due to the charges is 65 1.5% for neamine,
ribostamycin and neomycin and 54 1% for paromomy-
cin and lividomycin (Table 1). These values are expected
to change in diﬀerent ionic-strength conditions.
Interestingly, it is possible to perform the same
calculations for neamine, ribostamycin, paromomycin
and neomycin by considering the experimental data on
the A site from Ref. (46). The ﬁt (with the number of
positive charges listed in Table 1) is also very good
with a= 0.72 ( 0.18) kcalmol
 1 per positive charge
and  = 1.0kcalmol
 1 for 150 ( 24) A ˚ 2. In this case, the
fraction of free energy due to the charges is 41.5 1.5%
for neamine, ribostamycin and neomycin and 31% for
paromomycin. The salt conditions in Ref. (46) were
150mM NaCl, 10mM HEPES, pH 7.4 in comparison of
25mM potassium acetate, 2mM magnesium acetate,
20mM Na cacodylate, pH 7.0 in our study. Notably,
the agreement with experimental data obtained with our
simple  G modeling is at least as good as the one obtained
in Ref. (47) with a much more elaborate method involving
the Poisson–Boltzmann equation.
In order to obtain an accurate comparison of amino-
glycoside binding to the HIV-1 DIS and to the ribosomal
A site, we performed an ITC experiment with neomycin in
the same experimental conditions than with the DIS, but
on a minimal ‘double A site’ RNA duplex. The latter has
already been used for crystallization and structure
solution of the bacterial A site with aminoglycosides
(31). The two A-site motifs are separated by a 6-bp helical
part ( 17A ˚ ) and can therefore be considered as indepen-
dent binding sites. This construct was chosen because it is
as close as possible to the DIS kissing-loop: both RNA
have two antibiotics binding sites and are of same size
(similar unspeciﬁc binding is therefore expected). In these
quite comparable conditions, a Kd of 1.55mM was found
for neomycin (Table 1 and Figure S5). Rather surpris-
ingly, neomycin thus binds the DIS kissing-loop complex
with a 40-fold higher aﬃnity than its natural target, the
bacterial ribosomal A site. In the light of the aminoglyco-
side/DIS crystal structure, this enhanced aﬃnity is well
explained by additional structure-speciﬁc interactions
between ring I and the phosphates of the DIS RNA.
These direct or cation-mediated interactions are speciﬁc to
the kissing-loop topology and cannot be observed in
equivalent aminoglycoside/A site complexes (25,26).
Stabilization of theDIS loop–loopinteraction upondrug
binding
We then analyzed the impact of aminoglycoside binding
on the DIS loop–loop helix stability using UV-melting.
To avoid problems in melting curves interpretation
[because of overlapping signals of the 7bp stem, the 6bp
loop–loop helix, and hairpin to duplex conversion (30)], a
27-nt DIS variant sequence was used to make possible the
distinction between the kissing-loop dissociation and the
stem melting: the stem of this DIS mutant was stabilized
by the substitution of two G-C for two A-U base pairs
(not involved into drug binding) and the addition of two
terminal G-C base pairs (Figure 5). This stabilization
shifted the melting of the stem toward higher temperatures
without aﬀecting the melting temperature of the loop–
loop helix. Control UV-melting experiments were ﬁrst
conducted in absence of ligand and with increas-
ing concentrations of RNA. The transition observed is
concentration-dependent, shifting from 38.5 to 448C when
the RNA concentration increased from 1.15 to 3.1mM, in
agreement with the bimolecular dissociation of the loop–
loop helix. From a van’t Hoﬀ analysis (48) we derived an
enthalpy of loop–loop interaction  H= 34kcalmol
 1
(Figure 5). Addition of aminoglycosides induced a
displacement of the loop–loop melting to higher tempera-
tures. The shift ( Tm) ranged from 7.58C upon addition
of ribostamycin, to 24.88C upon addition of neomycin
(Table 2 and Figure S6). The stabilization is roughly
consistent with aﬃnities determined previously: a drug
with a low Kd induces a strong stabilization of the kissing-
loop complex. A negative control was also performed with
hygromycin, which did not signiﬁcantly stabilize the
kissing-loop complex ( Tm=0.38C). Thus, aminoglyco-
sides can be separated into two clusters: ribostamycin,
neamine and apramycin (with Kd values in the 5–12mM
range) stabilize poorly the kissing-loop interaction (less
than 148C), whereas paromomycin, neomycin and livido-
mycin having much lower Kd values (1.3mM, 34 and
32nM, respectively) stabilize it by more than 208C. These
results correlate very well with previous biochemical
experiments performed on much larger RNA fragments
encompassing the complete 50-untranslated region of the
viral genome (26). It was found that neomycin, lividomy-
cin and paromomycin strongly increased the lifetime of
the DIS kissing-loop complex, whereas no signiﬁcant
eﬀect was observed in presence of neamine and ribosta-
mycin. We can therefore postulate that beyond a certain
value of the  Tm, comprised between 9.18C (for neamine)
and 19.58C (for lividomycin), aminoglycoside binding
stabilize the DIS kissing-loop in the context of large viral
RNA fragments in vitro.
These results also suggest that UV-melting is a simple
and convenient way to monitor aminoglycoside binding to
the DIS kissing-loop complex: using a multicell holder, it
is possible to automatically screen several drugs at the
same time and to derive information about aﬃnity and
stabilization of these molecules.
Aminoglycoside binding inhibits theDISkissing-loop to
extended duplex transition
The impact of aminoglycoside binding on the DIS kissing-
loop complex to extended duplex conversion was eval-
uated using biochemical techniques. It was shown that
this NCp7-assisted conversion can also be facilitated by
incubating the DIS at 558C, without NCp7 (49,50),
Nucleic Acids Research, 2007, Vol. 35, No. 21 7135resulting in duplex dimers of similar conformations (51).
The distinction between the DIS kissing-loop and
extended duplex dimers can be performed by gel electro-
phoresis in semi-denaturing conditions: in absence of
magnesium and at room temperature, the loop–loop
interaction is unstable, resulting in DIS hairpin mono-
mers, whereas duplex dimers are resistant to such
experimental conditions (20,52). A control DIS monomer
is obtained using the DIS C275 mutant, where the U275C
mutation in the self-complementary sequence prevents
formation of a kissing-loop dimer and strongly disfavors
the formation of the duplex dimer (30).
After 1h of incubation at 558C, a majority of DIS was
converted into duplex in absence of drug (Figure 6, lane
‘0’ at 558C), whereas only trace amount of duplex
was visible after 1h at 208C (Figure 6, lane ‘0’ at 208C)
or at 378C (data not shown). Addition of various
aminoglycoside antibiotics (100mM ﬁnal concentration)
diﬀerently aﬀects this conversion (Figure 6). Hygromycin
(used here as a negative control) strongly favors the
duplex formation at 558C and the amount of duplex also
increased with ribostamycin, but was not signiﬁcantly
aﬀected by apramycin or neamine. The most pronounced
and interesting eﬀect was observed with the three drugs
having the strongest stabilization eﬀect on the kissing-loop
according to UV-melting studies: lividomycin, neomycin
and paromomycin strongly inhibit the conversion into
duplex (Figure 6). In particular, no trace of duplex dimer
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Figure 5. (a) 27-mer RNA sequence used for UV-melting studies. Mutations introduced to stabilize the DIS stem are boxed in gray. The self-
complementary sequence is bolded. (b) van’t Hoﬀ analysis of the concentration-dependent melting curve for the DIS kissing-loop interaction in
absence of drug.
Figure 6. Semi-denaturing gel obtained after 1h of incubation of DIS
kissing-loop at 558C (or 208C) in presence of 100mM hygromycin,
lividomycin, neomycin, paromomycin, apramycin, ribostamycin and
neamine. The lower band corresponds to DIS hairpin resulting from
kissing-loop complex dissociation in semi-denaturing conditions,
whereas the top band corresponds to DIS duplex. The ‘C275’ lane is
a DIS U275C mutant that cannot form a kissing-loop complex and is
poorly converted into duplex. The ‘0’ lane corresponds to the addition
of water instead of drug.
Table 2. Melting temperatures observed for the DIS kissing-loop
complex alone (for an RNA concentration of 2.5mM) and in presence
of various aminoglycoside antibiotics at 10.7mM ﬁnal concentration
Tm (8C)  Tm (8C)
RNA only 43.0 ( 1.4) –
Neamine 52.1 ( 2.3) 9.1
Ribostamycin 50.5 ( 2.6) 7.5
Paromomycin 63.4 ( 0.9) 20.4
Neomycin 67.8 ( 1.1) 24.8
Lividomycin 62.5 ( 0.4) 19.5
Apramycin 56.9 ( 0.7) 13.9
Hygromycin 43.3 ( 4.3) 0.3
7136 Nucleic Acids Research, 2007, Vol. 35, No. 21could be observed with neomycin, which is also the best
DIS kissing-loop complex binder.
To check that the observed monomer in semi-
denaturing conditions really results from kissing-loop
dissociation, and not from an inhibition of the loop–loop
interaction, an aliquot of the RNA incubated at 558Ci n
presence of aminoglycosides was loaded on a gel in
native conditions at 48C in presence of magnesium. This
experiment conﬁrmed that lividomycin, neomycin and
paromomycin do not prevent the kissing-loop interaction
at 558C (Figure S7), but indeed block the kissing-loop
to dimer conversion. Experiments performed with increas-
ing aminoglycoside concentration show an IC50 for
neomycin, lividomycin and paromomycin of  500mMa t
558C (Figure S8 and data not shown). Inhibition of the
conversion could also be observed with apramycin at
higher level of drug concentration (>1mM, data not
shown).
CONCLUSIONS
Here we show that apramycin, but not hygromycin,
binds the DIS kissing-loop complex. Based on molecular
modeling, the apramycin/DIS interaction is expected to
diﬀer from the interaction between the DIS and the
4,5-disubstituted 2-DOS aminoglycosides. In particular,
the minor groove of the DIS stem might be involved into
apramycin recognition in addition to the loop–loop inter-
strand helix, thus suggesting new potential drug/RNA
interactions for rational drug design. Binding parameters
of several aminoglycosides were determined by ITC
microcalorimetry, showing a sub-micromolar aﬃnity of
the DIS kissing-loop complex for neomycin and livido-
mycin, and low micromolar aﬃnity for paromomycin
and apramycin. On the contrary, no speciﬁc binding was
detected for hygromycin and for the 4,6-disubstituted
2-DOS tobramycin.
Binding of paromomycin, lividomycin and neomycin
results in a strong stabilization of the DIS loop–loop
interaction that was monitored by UV melting. This
stabilization traps the kissing-loop complex, blocking its
heat-assisted conversion into the extended duplex form of
the DIS. We are now investigating possible eﬀects of
this stabilization on various steps of the viral replication.
First, viral reverse transcription might be aﬀected at the
late stage of the ( ) strand DNA synthesis, since
stabilization of the kissing-loop complex could induce
pauses of the viral reverse transcriptase and its dissocia-
tion from the reverse transcription complex. Second,
the eﬀect of aminoglycosides on the NCp7 chaperone
activity has to be evaluated. This positively charged small
protein covering the viral genome did not obstruct
aminoglycoside access to the DIS in viral particles or
infected cells (26), but might indeed hinder the aminogly-
coside eﬀect in vivo through its eﬃcient nucleic acids
chaperone activity. Consequently, we are currently ana-
lyzing the eﬀect of aminoglycosides on the NCp7-assisted
isomerization of the kissing-loop complex in the extended
duplex.
Finally, it was shown that DIS kissing-loop interactions
can be used as a building block for nucleic acid-based
nanostructures with linear or circular interactions (53–55).
We suggest that aminoglycoside antibiotics might be used
as a ‘speciﬁc glue’ to enhance the stability of such
nanostructures based on DIS kissing-loop motifs. The
possibility of varying the stability of particular interac-
tions would open the way of making transient bonds,
which should permit building up more complicate
structures.
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